Market Trends of Global Infectious Disease Drugs Industry
This section covers the major market trends shaping the Infectious Disease Drugs Market according to our research experts:
Malaria Segment is Expected to Hold a Significant Market Share over the Forecast Period
The malaria disease segment is expected to grow over the forecast period owing to the increasing prevalence of malaria disease in developing and under-developed countries such as India, Africa, and other Southeast Asian countries, rising research and development activities by the market players as well as the health care organizations.
The rising prevalence of malaria diseases is the key factor driving the demand for infectious disease drugs over the forecast period. For instance, according to the World Health Organization (WHO) data published in 2021, Sub-Saharan Africa likely continues to endure the burden of malaria, accounting for approximately 95% of all cases and 96% of all deaths. Furthermore, as per the report "World Malaria Report" published by WHO in 2021, 29 of the 85 malaria-endemic countries accounted for 96% of all malaria cases in 2020. India contributed approximately 1.7% of malaria cases and 1.2% of deaths globally. As per the same source, there were an estimated 241 million malaria cases in 2020, as compared to 227 million cases in 2019. Thus, the increasing number of malaria cases across countries is likely to increase the demand for malarial drugs, which further increases the demand for infectious diseases, thereby increasing the market growth.
In addition, the rising research and development activities and an increasing number of company collaborations for the development of product pipelines are providing beneficial opportunities for the malarial drugs market over the forecast period. For instance, in April 2021, Janssen Pharmaceutica NV collaborated with Walter and Eliza Hall Institute of Medical Research (WEHI), an Australian Medical Research Center, to develop potential new antimalarial drug candidates. The collaborative research team discovered compounds with antimalarial activity within a collection of 80,000 drug-like molecules in the Janssen Jump-stARter Compound Library. The most promising candidates are now being further developed by the researchers towards potential antimalarial drugs.
Thus, the increasing burden of malaria disease in various countries and increasing research and development activities are likely to increase the demand for infectious disease drugs, thereby boosting the market growth.
North America is Expected to Hold Largest Market Share over the Forecast Period
North America is expected to hold a major market share in the infectious diseases drugs market owing to the rising prevalence of infectious diseases and the presence of better healthcare infrastructure, the presence of key market players, and increasing awareness programs.
The rising prevalence of infectious diseases is the key factor driving the growth of the market in the region. For instance, according to the World Health Organization, in 2021, more than 723,000 cases of malaria were reported in America in 2019, an increase of 7% as compared to 2010. Similarly, according to statistics published by MedAlertHelp, in 2022, about 5% to 20% of Americans are diagnosed with influenza every year. Further, according to the data published by the Centers for Disease Control and Prevention, in October 2021, overall, 35 million flu-related illnesses, 380,000 flu-related hospitalizations, 20,000 flu-related deaths, and 16 million flu-related medical visits were reported in the 2019-2020 season.
In addition, the increasing focus of companies and organizations on developing drugs for treating infectious diseases and rising product launches in the region is expected to boost the market growth in the United States. For instance, in September 2021, TB Alliance, a non-profit organization, granted a non-exclusive license to Lupin to manufacture the anti-TB drug pretomanid. Similarly, in March 2021, Gilead acquired Myr Pharmaceuticals for EUR 145 billion. This acquisition provides Gilead access to Hepcludex (bulevirtide), which was conditionally approved by the European Medicines Agency for the treatment of chronic hepatitis delta virus (HDV) in adults with compensated liver disease in July 2020.
Thus, owing to all the above-mentioned factors, the market is expected to witness high growth over the forecast period.
